ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / AEON / options
MRKR (35) NEUP (31) RADX (46) KPTI (29) ⌘ Pro Terminal β†’

AEON Biopharma Inc. (Class A) (AEON) Options Positioning, Max Pain & Unusual Sweeps

$0.27 -0.36% NYSE β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.27

AEON Biopharma Inc. (Class A) (AEON) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D β€’ SELL / AVOID Cap $16.2M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AEON Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is AEON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, AEON Biopharma Inc. (Class A) (NYSE: AEON) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $0.27 (-0.36% 1D, market cap $16.2M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, AEON ranks #344 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does AEON compare to MRKR and NEUP in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AEON carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, MRKR (Marker Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $16.3M) and NEUP (Neuphoria Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -11.8%, cap $16.5M). Among the 5-stock peer group, AEON leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AEON?
β–Ό

Per AEON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001837607), AEON Biopharma Inc. (Class A) generated $35.8M in revenue (-82.5% YoY), -$39.2M in net income, and -$17.3M in free cash flow against $5.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.27 (-0.25%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 9/20 (D) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (46/100 Β· D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D
025507510046
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- Β· Rk D
Cash (9)Whales (12)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-3.7% Base Target
$2 Bull$0 Base$0 Bear
πŸ“¬ FREE AEON RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for AEON)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
πŸ” WHY AEON SCORES 46/100 (D) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+12/20 pts (26% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 1/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
38
Grade E$0.23+0% Next Q
Q2 (-2Q)
41
Grade D$0.23+8.7% Next Q
Q3 (-1Q)
43
Grade D$0.25+8% Next Q
Current
46
Grade D$0.27-6.1% Hist 90D Ξ±
Trajectory: E (38) β†’ D (46)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a AEON Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While AEON currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.26) and Max Pain ($0.28) forces dealer call-delta covering toward $1.52.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AEONβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œAEON Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (AEON)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for AEON.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AEON)

  • βœ“Walkthrough of AEON's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
AEON // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -71.58%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $0.29H $0.29L $0.27C $0.27VOL 774.6K
RES: $0.47SUP: $0.23SMA50: $0.26SMA200: $0.67
$1.10$0.85$0.60$0.35$0.10RES $0.47SUP $0.23$0.272026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AEON Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ AEON Butterfly Map β†’ + Track AEON β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -82.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AEON today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for AEON. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AEON today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AEON)

Health Care Rank #344 of 1015 βš”οΈ MRKR vs AEON Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (AEON vs. MRKR, NEUP, RADX, KPTI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, AEON Biopharma Inc. (Class A) (AEON) ranks #344 by composite RQD confidence (46/100, grade D) and #846 by equity capitalization ($16.2M). Within this direct 5-issuer industry benchmark cohort, AEON leads on earnings valuation at N/A trailing P/E, while NEUP leads on capital efficiency and profitability with -11.8% ROIC and β€” gross margin. AEON currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AEON ACTIVE
AEON Biopharma Inc. (Class A)
D 46/100 β€” β€” -35.0% -0.36% $16.2M Benchmark Subject
MRKR
Marker Therapeutics Inc.
D- 35/100 β€” β€” -35.0% -8.05% $16.3M /mrkr-vs-aeon β†’
NEUP
Neuphoria Therapeutics Inc.
E 31/100 β€” β€” -11.8% -0.33% $16.5M /neup-vs-aeon β†’
RADX
Radiopharm Theranostics Limited
D 46/100 β€” β€” β€” -8.05% $15.6M /radx-vs-aeon β†’
KPTI
Karyopharm Therapeutics Inc.
E 29/100 β€” β€” -35.0% -83.08% $15.0M /kpti-vs-aeon β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001837607 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), AEON Biopharma Inc. (Class A) (AEON) reported GAAP revenue of $35.8M (-82.5% vs. FY2024 revenue of $204.4M ) , GAAP net income of -$39.2M, operating cash flow of -$17.3M, and free cash flow of -$17.3M (+14.7% YoY). On the balance sheet, AEON closed FY2025 with $5.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $35.8M -$39.2M -$17.3M -$17.3M $5.6M β€”
FY2024 (FY) 2024-12-31 $204.4M $42.0M -$20.3M -$20.3M $3.1M β€”

3. AEON Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AEON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, AEON Biopharma Inc. (Class A) (NYSE: AEON) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $0.27 (-0.36% 1D, market cap $16.2M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, AEON ranks #344 in composite RQD confidence.

How does AEON compare to MRKR and NEUP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AEON carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, MRKR (Marker Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $16.3M) and NEUP (Neuphoria Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -11.8%, cap $16.5M). Among the 5-stock peer group, AEON leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AEON?

Per AEON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001837607), AEON Biopharma Inc. (Class A) generated $35.8M in revenue (-82.5% YoY), -$39.2M in net income, and -$17.3M in free cash flow against $5.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AEON trading relative to its 50-day, 200-day, and 52-week technical levels?

AEON last traded at $0.27 (-0.36% on volume of 323,992 shares), positioning the stock +3.85% above its 50-day simple moving average ($0.26) and -59.70% below its 200-day simple moving average ($0.67). Across its 52-week range of $0.18 to $1.45, AEON sits at the 7.1% percentile with a 14-day RSI of 52.5 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.00 to $0.30).

Direct Sub-Reports: AEON RQD Cockpit AEON 12M Forecast AEON Earnings & Move AEON Dividends & DRIP AEON Insiders & 13F AEON Whale Options AEON Profit Sankey AEON News & Why
ROARABLE RATING BRIEF β€’ RQD 46/100 (D) βœ“ SEC XBRL & RQD VERIFIED

AEON β€” AEON Biopharma Inc. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

AEON Biopharma Inc. (Class A) (AEON) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $0.27 (-0.36% 1D, market capitalization $16.2M).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (12/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

AEON Biopharma Inc. (Class A) is a NYSE-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations..0B, which is inconsistent with the $17.4M figure in the market data and should be treated as unresolved. β€” describes its products, customers, or revenue model. Per the financials, reported revenue is β€” for both FY 2025 and FY 2024.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), AEON Biopharma Inc. (Class A) (AEON) reported $35.8M in annual revenue (up from $204.4M in FY2024, -82.5% YoY) and -$39.2M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($204.4M revenue, $42.0M net income) through FY2025, AEON scaled operating cash flow to -$17.3M and free cash flow to -$17.3M, backed by $5.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D β€’ RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 12/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 12/20, sustained execution supports upside toward the upper end of the $0.18 – $1.45 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or second-order bottlenecks are identified in the source data. β€” for specific supply-chain relationships. The sector and industry classification (Health Care; Biotechnology: Pharmaceutical Preparations) is the only contextual link provided.

  • Key Question #1: Can AEON sustain or expand its β€” operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $35.8M and free cash flow of -$17.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is AEON's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

AEON Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for AEON Biopharma Inc. (Class A) (AEON) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to AEON Debate Forum (3) ↓
🟑 MARKET WIRE Yahoo Finance β€’ 1d ago
Stock Splits Calendar for:

Yahoo Finance report covering AEON Biopharma Inc. (Class A) (AEON) market action, institutional positioning, and fundamental catalysts.

Read Full Source β†—
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AEON Bull vs. Bear Conversation Board β€” What's Your Call at $0.27?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AEON 🐻 33% BEARISH CONVICTION
1. Pick Your Side on AEON:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER β€’ FCF Compounder Hunter πŸ‚ BULLISH 🎯 Target: $0.32 (+18.5%)
πŸ“Œ Pinned Debate

The stock is up 11.36% with a moderate 14/20 whale-flow pillar score per the RQD rating.

Long AEON at $0.27 targeting $0.32. The stock is up 11.36% with a moderate 14/20 whale-flow pillar score per the RQD rating.. Institutional whale score is 12/20 and the risk/reward vs. the $0.18 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader πŸ‚ BULL

Both sides have a point here β€” AEON's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER β€’ Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $0.22 (-18.5%)
Spot @ $0.27

ROIC of -35%, FCF yield of 0%, and a Piotroski F-Score of 1/9 point to weak fundamentals and a Roarable Sell verdict.

Sitting on the sidelines or leaning short AEON above $0.27. ROIC of -35%, FCF yield of 0%, and a Piotroski F-Score of 1/9 point to weak fundamentals and a Roarable Sell verdict.. Until Fundamental Cash Engine (9/20) and FCF yield (0.0%) inflect higher, upside is capped near $1.45.

LIVE TAPE